Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06347809 · ClinicalTrials.gov registry record
DNA Methylation in Adenocarcinoma of the Prostate: Analysis of Validated Biomarkers in Urine
A clinical trial, sponsored by Mayo Clinic.
- Terminated
- Registry status
- 24
- Enrollment target
NCT06347809: Clinical Trial study, sponsored by Mayo Clinic.
NCT06347809 is a clinical trial that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06347809 was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- 24 participants
- Enrollment target
Study Summary
This study explores the potential use of DNA markers in the detection of prostate cancer and patient perceptions of this screening approach and other current or future prostate cancer screening and diagnostic tests.
Interventions
- OTHER Non-Interventional Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2019-01-23 |
| Est. Completion | 2025-07-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06347809
The ClinicalTrials.gov registry entry for NCT06347809 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT06347809 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06347809 about?
NCT06347809 is a clinical study titled "DNA Methylation in Adenocarcinoma of the Prostate: Analysis of Validated Biomarkers in Urine". This study explores the potential use of DNA markers in the detection of prostate cancer and patient perceptions of this screening approach and other current or future prostate cancer screening and diagnostic tests.
What is the current status of trial NCT06347809?
This trial is currently terminated. The enrollment target is 24 participants. The study started on 2019-01-23. Estimated completion is 2025-07-31.
What interventions are being tested in trial NCT06347809?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT06347809?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.